Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Oct;68(4):1108–1112. doi: 10.1172/JCI110336

Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition.

E Dejana, C Cerletti, C de Castellarnau, M Livio, F Galletti, R Latini, G de Gaetano
PMCID: PMC370901  PMID: 6793630

Abstract

Aspirin inhibits cyclooxygenase, thus preventing thromboxane A2 production in blood platelets and prostacyclin in vascular cells. Aspirin is rapidly hydrolyzed to salicylate in the circulation. The objectives of this study were (a) to evaluate whether administration of salicylate, though ineffective by itself, prevents the inhibitory effect of aspirin on platelet and/or vascular cyclooxygenase activity; (b) to verify whether salicylate accumulating in blood after aspirin administration interferes with the pharmacological activity of further doses of aspirin. Pretreatment of rats with sodium salicylate (25-100 mg/kg i.p.) resulted in dose-related prevention of the effect of a subsequent dose of aspirin (2.5-10 mg/kg i.v.) on both platelet and vascular cells. Sodium salicylate appeared to amplify the greater response of platelets to aspirin compared with vessel wall. Pretreatment of rats with repeated high doses of aspirin (200 mg/kg) resulted after 24 h in blood salicylate levels (150-200 microgram/ml) that significantly prevented the inhibitory effect of a subsequent dose of aspirin on newly synthesized vascular prostacyclin. Blood salicylate levels obtained after 36 or 48 h (less than 50 microgram/ml) were too low to blunt aspirin's effect. The interference with aspirin of its major endogenous metabolite should be borne in mind when interpreting results obtained with high dose aspirin or during repeated administration of this drug.

Full text

PDF
1108

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali M., McDonald J. W. Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet cyclooxygenase activity. Prostaglandins Med. 1979 Dec;3(6):327–332. doi: 10.1016/0161-4630(79)90025-9. [DOI] [PubMed] [Google Scholar]
  2. Baenziger N. L., Dillender M. J., Majerus P. W. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem Biophys Res Commun. 1977 Sep 9;78(1):294–301. doi: 10.1016/0006-291x(77)91253-0. [DOI] [PubMed] [Google Scholar]
  3. Buchanan M. R., Dejana E., Cazenave J. P., Richardson M., Mustard J. F., Hirsh J. Differences in inhibition of PGI2 production by aspirin in rabbit artery and vein segments. Thromb Res. 1980 Nov 15;20(4):447–460. doi: 10.1016/0049-3848(80)90283-2. [DOI] [PubMed] [Google Scholar]
  4. Burch J. W., Baenziger N. L., Stanford N., Majerus P. W. Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sci U S A. 1978 Oct;75(10):5181–5184. doi: 10.1073/pnas.75.10.5181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Czervionke R. L., Smith J. B., Hoak J. C., Fry G. L., Haycraft D. L. Use of a radioimmunoassay to study thrombin-induced release of PGI2 from cultured endothelium. Thromb Res. 1979;14(4-5):781–786. doi: 10.1016/0049-3848(79)90132-4. [DOI] [PubMed] [Google Scholar]
  6. Dejana E., Barbieri B., Cerletti C., Livio M., de Gaetano G. Impaired thromboxane production by newly formed platelets after aspirin administration to thrombocytopenic rats. Br J Haematol. 1980 Nov;46(3):465–469. doi: 10.1111/j.1365-2141.1980.tb05994.x. [DOI] [PubMed] [Google Scholar]
  7. Hamberg M., Svensson J., Wakabayashi T., Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A. 1974 Feb;71(2):345–349. doi: 10.1073/pnas.71.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hanley S. P., Bevan J., Cockbill S. R., Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet. 1981 May 2;1(8227):969–971. doi: 10.1016/s0140-6736(81)91733-5. [DOI] [PubMed] [Google Scholar]
  9. Marcus A. J. Aspirin and thromboembolism--a possible dilemma. N Engl J Med. 1977 Dec 8;297(23):1284–1285. doi: 10.1056/NEJM197712082972312. [DOI] [PubMed] [Google Scholar]
  10. Masotti G., Galanti G., Poggesi L., Abbate R., Neri Serneri G. G. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979 Dec 8;2(8154):1213–1217. doi: 10.1016/s0140-6736(79)92334-1. [DOI] [PubMed] [Google Scholar]
  11. Merino J., Livio M., Rajtar G., de Gaetano G. Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation. Biochem Pharmacol. 1980 Apr 15;29(8):1093–1096. doi: 10.1016/0006-2952(80)90401-3. [DOI] [PubMed] [Google Scholar]
  12. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  13. Moncada S., Vane J. R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978 Sep;30(3):293–331. [PubMed] [Google Scholar]
  14. Pareti F. I., D'Angelo A., Mannucci P. M., Smith J. B. Platelets and the vessel wall: how much aspirin? Lancet. 1980 Feb 16;1(8164):371–372. [PubMed] [Google Scholar]
  15. Preston F. E., Whipps S., Jackson C. A., French A. J., Wyld P. J., Stoddard C. J. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med. 1981 Jan 8;304(2):76–79. doi: 10.1056/NEJM198101083040203. [DOI] [PubMed] [Google Scholar]
  16. Roncaglioni M. C., di Minno G., Reyers I., de Gaetano G., Donati M. B. Increased prostacyclin-like activity in vascular tissues from rats on long-term treatment with an oestrogen-progestagen combination. Thromb Res. 1979;14(4-5):793–797. doi: 10.1016/0049-3848(79)90134-8. [DOI] [PubMed] [Google Scholar]
  17. Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076. doi: 10.1073/pnas.72.8.3073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rowland M., Riegelman S. Determination of acetylsalicylic acid and salicylic acid in plasma. J Pharm Sci. 1967 Jun;56(6):717–720. doi: 10.1002/jps.2600560611. [DOI] [PubMed] [Google Scholar]
  19. Rowland M., Riegelman S., Harris P. A., Sholkoff S. D. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci. 1972 Mar;61(3):379–385. doi: 10.1002/jps.2600610312. [DOI] [PubMed] [Google Scholar]
  20. Vargaftig B. B. The inhibition of cyclo-oxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur J Pharmacol. 1978 Aug 1;50(3):231–241. doi: 10.1016/0014-2999(78)90355-2. [DOI] [PubMed] [Google Scholar]
  21. Villa S., Livio M., de Gaetano G. The inhibitory effect of aspirin on platelet and vascular prostaglandins in rats cannot be completely dissociated. Br J Haematol. 1979 Jul;42(3):425–431. doi: 10.1111/j.1365-2141.1979.tb01151.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES